- Home
- VALU vs PRTA Comparison
VALU vs PRTA Comparison
Compare VALU & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- PRTA
- Stock Information
- Founded
- VALU 1931
- PRTA 2012
- Country
- VALU United States
- PRTA Ireland
- Employees
- VALU N/A
- PRTA N/A
- Industry
- VALU Investment Managers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- PRTA Health Care
- Exchange
- VALU Nasdaq
- PRTA Nasdaq
- Market Cap
- VALU 358.0M
- PRTA 346.4M
- IPO Year
- VALU N/A
- PRTA N/A
- Fundamental
- Price
- VALU $37.78
- PRTA $6.22
- Analyst Decision
- VALU
- PRTA Buy
- Analyst Count
- VALU 0
- PRTA 9
- Target Price
- VALU N/A
- PRTA $27.67
- AVG Volume (30 Days)
- VALU 2.4K
- PRTA 1.7M
- Earning Date
- VALU 07-25-2025
- PRTA 08-07-2025
- Dividend Yield
- VALU 3.26%
- PRTA N/A
- EPS Growth
- VALU 17.96
- PRTA N/A
- EPS
- VALU 2.28
- PRTA N/A
- Revenue
- VALU $35,695,000.00
- PRTA $137,935,000.00
- Revenue This Year
- VALU N/A
- PRTA N/A
- Revenue Next Year
- VALU N/A
- PRTA $122.02
- P/E Ratio
- VALU $16.54
- PRTA N/A
- Revenue Growth
- VALU N/A
- PRTA 54.55
- 52 Week Low
- VALU $32.94
- PRTA $4.32
- 52 Week High
- VALU $57.68
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- VALU 45.67
- PRTA 52.88
- Support Level
- VALU $38.00
- PRTA $6.31
- Resistance Level
- VALU $39.73
- PRTA $6.77
- Average True Range (ATR)
- VALU 0.67
- PRTA 0.30
- MACD
- VALU -0.00
- PRTA 0.07
- Stochastic Oscillator
- VALU 1.17
- PRTA 54.26
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.